JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?
- PMID: 38622986
- DOI: 10.1515/hmbci-2023-0088
JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?
Abstract
The emergence of the SARS-CoV-2 Omicron variant, classified as a Variant of Concern (VoC) in November 2021, marked a significant shift in the COVID-19 landscape. This study investigates the subsequent development of a novel Omicron sublineage, JN.1, which displays distinctive mutations in the spike protein. The study delves into the phylogenetic differences between these variants and their potential implications. A comprehensive analysis of the genomic profiles and mutation patterns of JN.1 and BA.2.86 was conducted, utilizing SARS-CoV-2 database. The study explores the unique mutations, such as S:L455S in JN.1, associated with increased transmissibility and immune escape. Furthermore, a comparison with prevalent strains like XBB.1.5 and HV.1 highlights the substantial genetic divergence of JN.1. JN.1, first detected in August 2023, exhibits a notable spike protein mutation profile, including the reappearance of earlier variants' mutations (E484K and P681R). The variant's increased transmissibility and immune evasion potential are attributed to specific spike protein mutations like R21T, S50L, V127F, R158G, and others. The study also explores the distribution and prevalence of JN.1 globally, with a focus on the rising cases in India. JN.1 poses a unique challenge as one of the most immune-evading variants, with potential implications for COVID-19 transmission. The study emphasizes the importance of monitoring and understanding emerging variants, especially those with distinct spike protein mutations. The observed cases in India highlight the need for vigilance and prompt public health responses. As JN.1 continues to evolve, ongoing surveillance, vaccination strategies, and adherence to preventive measures are crucial to mitigating its potential impact on global public health.
Keywords: COVID-19; JN.1 variant; omicron variant; variety of concern (VOC); variety of interest (VOI).
© 2024 Walter de Gruyter GmbH, Berlin/Boston.
Similar articles
-
The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health.Ther Adv Infect Dis. 2025 Jan 30;12:20499361251314763. doi: 10.1177/20499361251314763. eCollection 2025 Jan-Dec. Ther Adv Infect Dis. 2025. PMID: 39896217 Free PMC article. Review.
-
Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3.mBio. 2025 Jun 11;16(6):e0350324. doi: 10.1128/mbio.03503-24. Epub 2025 Apr 29. mBio. 2025. PMID: 40298448 Free PMC article.
-
Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia.Acta Microbiol Immunol Hung. 2024 May 8;71(2):165-171. doi: 10.1556/030.2024.02247. Print 2024 Jul 2. Acta Microbiol Immunol Hung. 2024. PMID: 38717854
-
Decoding omicron: Genetic insight into its transmission dynamics, severity spectrum and ever-evolving strategies of immune escape in comparison with other SARS-CoV-2 variants.Diagn Microbiol Infect Dis. 2025 Mar;111(3):116705. doi: 10.1016/j.diagmicrobio.2025.116705. Epub 2025 Jan 23. Diagn Microbiol Infect Dis. 2025. PMID: 39889436
-
Comprehensive Analysis of Omicron Subvariants: EG.5 Rise, Vaccination Strategies, and Global Impact.Curr Drug Targets. 2024;25(8):517-525. doi: 10.2174/0113894501296586240430061915. Curr Drug Targets. 2024. PMID: 38726782 Review.
Cited by
-
The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants.Int J Mol Sci. 2024 Aug 31;25(17):9498. doi: 10.3390/ijms25179498. Int J Mol Sci. 2024. PMID: 39273444 Free PMC article.
-
A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants.Mol Biomed. 2025 Mar 4;6(1):13. doi: 10.1186/s43556-025-00258-7. Mol Biomed. 2025. PMID: 40035925 Free PMC article.
-
The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health.Ther Adv Infect Dis. 2025 Jan 30;12:20499361251314763. doi: 10.1177/20499361251314763. eCollection 2025 Jan-Dec. Ther Adv Infect Dis. 2025. PMID: 39896217 Free PMC article. Review.
-
Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination.Viruses. 2024 Nov 29;16(12):1860. doi: 10.3390/v16121860. Viruses. 2024. PMID: 39772170 Free PMC article.
-
Fortifying defenses: Tactical safety protocols for COVID-19 sub-variant JN.1 in healthcare and laboratory settings.J Family Med Prim Care. 2025 Jan;14(1):78-84. doi: 10.4103/jfmpc.jfmpc_170_24. Epub 2025 Jan 13. J Family Med Prim Care. 2025. PMID: 39989551 Free PMC article.
References
-
- World Health Organization . Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern; 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.... .
-
- Kamble, P, Daulatabad, V, Patil, R, John, NA, John, J. Omicron variant in COVID-19 current pandemic: a reason for apprehension. Horm Mol Biol Clin Invest 2022;44:89–96. PMID: 36064193 https://doi.org/10.1515/hmbci-2022-0010 . - DOI
-
- Centers for Disease Prevention and Control . Science brief: omicron (B.1.1.529) variant; 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scienti... [Accessed 4 Dec 2021].
-
- Karim, SSA, Karim, QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398:2126–8. https://doi.org/10.1016/s0140-6736(21)02758-6 . - DOI
-
- Corum, J, Zimmer, C. Tracking omicron and other coronavirus variants; 2021. https://www.nytimes.com/interactive/2021/health/coronavirus-variant-trac... [Accessed 2 Dec 2021].
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous